<DOC>
	<DOCNO>NCT02472977</DOCNO>
	<brief_summary>The purpose study determine whether combination Ulocuplumab Nivolumab safe effective treatment pancreatic cancer small cell lung cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Ulocuplumab Nivolumab Subjects With Solid Tumors</brief_title>
	<detailed_description>- Intervention model : Single group Stage 1 DLT , Parallel - Data Monitoring Committee : No ( Stage 1 ) Yes ( Stage 2 Randomized Ph2 )</detailed_description>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com SCLC PAC advance spread part body Treated least one chemotherapy work cancer relapse Minimal limitation activity daily live measure Eastern Cooperative Oncology Group ( ECOG ) score 01 Patients cancer spread brain Active , know suspected autoimmune disease Prior treatment drug target T cell costimulation pathway ( checkpoint inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>